Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals shows raised 2025 guidance at June 4 Jefferies conference

Positive Impact 2 of 5 guidance Written later

ANI Pharmaceuticals filed its investor presentation for the Jefferies Global Healthcare Conference, where CEO Nikhil Lalwani will speak on June 4, 2025. The slides restate 2025 guidance issued on May 9, 2025, which the company describes as its second guidance raise of the year, and they report first-quarter 2025 revenue and profit growth. The filing presents previously disclosed figures rather than new results, but the guidance increase is relevant to shareholders.

Key points

  • 2025 net revenue guidance is $768 million to $793 million, up from $756 million to $776 million previously.
  • 2025 adjusted non-GAAP EBITDA guidance is $195 million to $205 million, up from $190 million to $200 million; adjusted diluted EPS guidance is $6.27 to $6.62, up from $6.12 to $6.49.
  • First-quarter 2025 total revenue was $197 million, up 43% year over year, and adjusted non-GAAP EBITDA was $51 million, up 35%.
  • Q1 ILUVIEN and YUTIQ revenue of $16 million was temporarily affected by factors the company listed, including sales force turnover; the company said demand accelerated in Q2 2025.

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECJun 4, 2025, 7:10 AM ET
Accession number0001023024-25-000058

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 04, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.